iodixanol has been researched along with Neoplasms in 3 studies
iodixanol: dimeric contrast media; structure given in first source
iodixanol : A dimeric, non-ionic, water-soluble, radiographic contrast agent, used particularly in coronary angiography.
Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Excerpt | Relevance | Reference |
---|---|---|
"To determine the incidence of post-contrast acute kidney injury (PC-AKI) and presumed contrast-induced acute kidney injury (CI-AKI) following contrast-enhanced CT (CECT) with intravenous application of a reduced dose of the iso-osmolar contrast agent iodixanol in cancer patients with chronic kidney disease." | 7.96 | Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. ( Bez, C; Hinterleitner, C; Horger, M; Werner, S, 2020) |
"To determine the incidence of post-contrast acute kidney injury (PC-AKI) and presumed contrast-induced acute kidney injury (CI-AKI) following contrast-enhanced CT (CECT) with intravenous application of a reduced dose of the iso-osmolar contrast agent iodixanol in cancer patients with chronic kidney disease." | 3.96 | Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol. ( Bez, C; Hinterleitner, C; Horger, M; Werner, S, 2020) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (66.67) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Werner, S | 1 |
Bez, C | 1 |
Hinterleitner, C | 1 |
Horger, M | 1 |
Terrenato, I | 1 |
Sperati, F | 1 |
Musicco, F | 1 |
Pozzi, AF | 1 |
di Turi, A | 1 |
Caterino, M | 1 |
de Lutio di Castelguidone, E | 1 |
Setola, SV | 1 |
Bellomi, M | 1 |
Neumaier, CE | 1 |
Conti, L | 1 |
Cigliana, G | 1 |
Merola, R | 1 |
Antenucci, A | 1 |
Orlandi, G | 1 |
Giordano, A | 1 |
Barba, M | 1 |
Canitano, S | 1 |
Xu, H | 1 |
Ohulchanskyy, TY | 1 |
Yakovliev, A | 1 |
Zinyuk, R | 1 |
Song, J | 1 |
Liu, L | 1 |
Qu, J | 1 |
Yuan, Z | 1 |
1 trial available for iodixanol and Neoplasms
Article | Year |
---|---|
Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Contrast Media; Female; Glomerular Filtration Rate; Humans; Iohexol; Italy; | 2018 |
2 other studies available for iodixanol and Neoplasms
Article | Year |
---|---|
Incidence of contrast-induced acute kidney injury (CI-AKI) in high-risk oncology patients undergoing contrast-enhanced CT with a reduced dose of the iso-osmolar iodinated contrast medium iodixanol.
Topics: Acute Kidney Injury; Adult; Aged; Aged, 80 and over; Contrast Media; Female; Humans; Incidence; Male | 2020 |
Nanoliposomes Co-Encapsulating CT Imaging Contrast Agent and Photosensitizer for Enhanced, Imaging Guided Photodynamic Therapy of Cancer.
Topics: Animals; Cell Line, Tumor; Cell Survival; Contrast Media; Liposomes; Mice, Inbred BALB C; Mice, Nude | 2019 |